Dr.paul Robbins

Biography

 Dr. Paul has obtained Ph.D-Molecular Biology, University of California, Berkeley, California.His professional series has1986 – 1990: Postdoctoral Fellow, Whitehead Institute for Biomedical Research, Cambridge, Massachusetts  1990 – 1995: Assistant Professor, Department of Molecular Genetics and Biochemistry, University of Pittsburgh School of Medicine  1991 – 2006: Director, Vector Core Facility, University of Pittsburgh School of Medicine  1996 – 1999: Associate Professor (with tenure), Department of Molecular Genetics and Biochemistry, University of Pittsburgh School of Medicine  1997 – 2001: Interim Director, Molecular and Cellular Oncology Program, University of Pittsburgh Cancer Institute  2000 – 2012: Professor, Department of Molecular Genetics and Biochemistry, University of Pittsburgh School of Medicine  2001 – 2012: Professor, Department of Orthopaedic Surgery, University of Pittsburgh School of Medicine  2001 – 2007: Director of Basic Research, Institute for Molecular Medicine, University of Pittsburgh School of Medicine  2003 – 2009: Co-Director, Paul Wellstone Cooperative Center of Excellence in Muscular Dystrophy  2004 – 2005: Interim Director, Clinical Vector and Vaccine Production Facility  2012 – Present: Professor, Department of Metabolism and Aging, The Scripps Research Institute, Jupiter Florida  2012 – Present: Adjunct Professor, Department of Molecular Genetics and Biochemistry, University of Pittsburgh School of Medicine. Dr has achieved awards has editorials and publications too.

Research Interest

 The laboratory is developing novel approaches to treat autoimmune (type 1 diabetes, rheumatoid arthritis), inflammatory (inflammatory bowel disease, delayed type hypersensitivity) and age-related degenerative diseases using biologics and small molecules. The therapeutic approaches being developed include: 1) AAV mediated gene transfer of anti-inflammatory or immunosuppressive agents; 2) peptide and small molecule inhibitors of the transcription factor of NF-kB; 3) novel osteogenic peptides; 4) adult stem cells; and 5) microvesicles exosomes) derived from immunoregulatory or stem cells able to block inflammation or promote regeneration. Although the majority of the studies are being performed in mouse models of disease, approaches to treat osteoarthritis by AAV gene transfer and Duchenne muscular dystrophy with a NF-kB inhibitory peptide will soon be entering the clinic.